Biotech M&A : Psychedelics' Coming as Eli Lilly's AtaiBeckley Acquisition Sets a Valuation Benchmark
Smartkarma
Jul 17
⬆ ATAI Life Sciences NV - Eli Lilly courting AtaiBeckley. Eli Lilly (NYSE: LLY) has announced that it intends to acquire AtaiBeckley (NASDAQ: ATAI) in a deal worth up to $3.8 billion.
Continue reading on Smartkarma:- https://www.smartkarma.com/insights/biotech-m-a-psychedelics-coming-as-eli-lilly-s-ataibeckley-acquisition-sets-a-valuation-benchmark?utm_source=tiger_community
By Water Tower Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/water-tower-research?utm_source=tiger_community
On ATAI Life Sciences NV (ATAI):- https://www.smartkarma.com/entities/atai-life-sciences-nv?utm_source=tiger_community
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.